ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.
暂无分享，去创建一个
D. Kwiatkowski | R. Riedel | K. Ganjoo | J. Hornick | R. Chugh | N. Desai | L. Cranmer | V. Ravi | B. A. Tine | M. Dickson | E. Gordon | S. Hou | A. Wagner | K. Harris | H. Du | A. Schmid | B. Grigorian